Sana M. Al‐khatib

Sana M. Al‐khatib's AcademicInfluence.com Rankings

Sana M. Al‐khatib

Medical

#3193

World Rank

#3648

Historical Rank

Cardiology

#326

World Rank

#337

Historical Rank

medical Degrees

Download Badge

Medical

Sana M. Al‐khatib's Degrees

Doctorate Medicine University of Jordan
Masters Clinical Research Duke University

Why Is Sana M. Al‐khatib Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sana M. Al‐khatib's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. (2018) (1054)
What clinicians should know about the QT interval. (2003) (617)
2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. (2017) (529)
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. (2017) (505)
Systematic review of the incidence of sudden cardiac death in the United States. (2011) (465)
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. (2010) (457)
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. (2018) (409)
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016) (396)
Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. (2007) (393)
2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. (2017) (372)
2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. (2016) (366)
Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. (2010) (343)
Pulmonary Vein Isolation for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized, Controlled Trials (2009) (286)
Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure: Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) (2006) (271)
Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. (2007) (267)
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. (2019) (261)
Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). (2014) (252)
Non-evidence-based ICD implantations in the United States. (2011) (247)
2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. (2016) (215)
2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. (2016) (209)
Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation (2013) (205)
The relation between patients' outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. (2005) (197)
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial (2012) (195)
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. (2016) (193)
The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. (2013) (187)
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation (2008) (183)
Early management of atrial fibrillation to prevent cardiovascular complications. (2014) (182)
Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. (2009) (180)
Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. (2010) (167)
Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016) (166)
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. (2013) (162)
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. (2006) (162)
Rates of and Factors Associated With Infection in 200 909 Medicare Implantable Cardioverter-Defibrillator Implants: Results From the National Cardiovascular Data Registry (2014) (155)
Rate- and Rhythm-Control Therapies in Patients With Atrial Fibrillation (2014) (151)
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. (2014) (148)
Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. (2003) (145)
Sustained Ventricular Arrhythmias Among Patients With Acute Coronary Syndromes With No ST-Segment Elevation: Incidence, Predictors, and Outcomes (2002) (144)
Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. (2002) (144)
2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. (2021) (141)
Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review (2018) (137)
2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary (2017) (137)
Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial (2013) (136)
Digoxin and Mortality in Patients With Atrial Fibrillation. (2018) (131)
Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. (2009) (129)
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias (2019) (126)
Clinical and Economic Implications of the Multicenter Automatic Defibrillator Implantation Trial-II (2005) (125)
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. (2016) (121)
Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. (2016) (120)
Rates of cardiopulmonary resuscitation training in the United States. (2014) (117)
Trends in Use of Implantable Cardioverter-Defibrillator Therapy Among Patients Hospitalized for Heart Failure: Have the Previously Observed Sex and Racial Disparities Changed Over Time? (2012) (117)
Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016) (115)
Patient and Implanting Physician Factors Associated With Mortality and Complications After Implantable Cardioverter-Defibrillator Implantation, 2002–2005 (2008) (114)
2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. (2016) (111)
Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. (2005) (106)
Clinical features of Wolff-Parkinson-White syndrome. (1999) (105)
Remote Monitoring of Implantable Cardioverter Defibrillators versus Quarterly Device Interrogations in Clinic: Results from a Randomized Pilot Clinical Trial (2010) (100)
Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. (2017) (97)
Temporal Differences in Out-of-Hospital Cardiac Arrest Incidence and Survival (2013) (95)
Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. (2013) (95)
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias (2019) (94)
QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. (2013) (91)
Survival Benefit of the Primary Prevention Implantable Cardioverter-Defibrillator Among Older Patients: Does Age Matter? An Analysis of Pooled Data From 5 Clinical Trials (2015) (90)
Catheter Ablation Versus Medical Therapy for Atrial Fibrillation. (2019) (90)
Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. (2014) (89)
Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. (2014) (88)
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. (2016) (83)
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. (2017) (81)
Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of <or=35%. (2007) (79)
Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. (2014) (77)
Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings from the Get With The Guidelines-Heart Failure Program (2016) (76)
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary (2019) (76)
HRS/ACCF expert consensus statement on pacemaker device and mode selection. (2012) (76)
2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. (2016) (76)
Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis (2017) (74)
Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. (2005) (73)
Observations on the transition from intermittent to permanent atrial fibrillation. (2000) (73)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. (2022) (71)
Surgery for Aortic Dilatation in Patients With Bicuspid Aortic Valves: A Statement of Clarification From the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016) (71)
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure (2010) (71)
2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. (2016) (68)
Risk stratification for arrhythmic events in patients with asymptomatic pre-excitation: A systematic review for the 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force (2016) (68)
Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. (2003) (67)
Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non–ST-Segment–Elevation Acute Coronary Syndromes (2012) (66)
Catheter Ablation for Ventricular Tachycardia in Patients with an Implantable Cardioverter Defibrillator (CALYPSO) Pilot Trial (2015) (64)
HRS/ACCF expert consensus statement on pacemaker device and mode selection. Developed in partnership between the Heart Rhythm Society (HRS) and the American College of Cardiology Foundation (ACCF) and in collaboration with the Society of Thoracic Surgeons. (2012) (63)
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial (2017) (62)
Association Between Left Ventricular Ejection Fraction Post-Cardiac Resynchronization Treatment and Subsequent Implantable Cardioverter Defibrillator Therapy for Sustained Ventricular Tachyarrhythmias (2013) (61)
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. (2019) (59)
Single-Photon Emission Computed Tomography Myocardial Perfusion Defects Are Associated With an Increased Risk of All-Cause Death, Cardiovascular Death, and Sudden Cardiac Death (2008) (58)
Preventing tomorrow's sudden cardiac death today: dissemination of effective therapies for sudden cardiac death prevention. (2008) (57)
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. (2014) (56)
Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. (2015) (54)
The Metabolic Syndrome and Risk of Sudden Cardiac Death: The Atherosclerosis Risk in Communities Study (2017) (54)
Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. (2015) (53)
Single-photon emission computed tomography myocardial perfusion imaging and the risk of sudden cardiac death in patients with coronary disease and left ventricular ejection fraction>35%. (2010) (52)
Implantable Cardioverter Defibrillator Therapy in Patients with Prior Coronary Revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCD‐HeFT) (2008) (52)
Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis. (2011) (52)
Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac death. (2007) (50)
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. (2008) (50)
Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke. (2015) (49)
Contemporary Management of Atrial Fibrillation: What Can Clinical Registries Tell Us About Stroke Prevention and Current Therapeutic Approaches? (2014) (49)
Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi‐morbidity: Insights from the ARISTOTLE trial (2019) (49)
A proposal for new clinical concepts in the management of atrial fibrillation. (2012) (48)
Risk Stratification for Arrhythmic Events in Patients With Asymptomatic Pre-Excitation: A Systematic Review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force (2016) (47)
Association Between Hospital Process Composite Performance and Patient Outcomes After In-Hospital Cardiac Arrest Care. (2016) (46)
Outcomes Associated With Extraction Versus Capping and Abandoning Pacing and Defibrillator Leads (2017) (45)
Reperfusion ventricular arrhythmia 'bursts' predict larger infarct size despite TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction. (2008) (45)
Race and gender variation in the QT interval and its association with mortality in patients with coronary artery disease: results from the Duke Databank for Cardiovascular Disease (DDCD). (2012) (44)
Surgical Maze procedure as a treatment for atrial fibrillation: a meta-analysis of randomized controlled trials. (2010) (43)
Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease (2014) (43)
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary (2020) (43)
Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. (2003) (42)
Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association. (2015) (41)
Extent of and Reasons for Nonuse of Implantable Cardioverter Defibrillator Devices in Clinical Practice Among Eligible Patients With Left Ventricular Systolic Dysfunction (2011) (41)
Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. (2009) (41)
American Heart Association Atrial Fibrillation Research Summit: A Conference Report From the American Heart Association (2011) (41)
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. (2015) (41)
Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? (2004) (40)
Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. (2001) (40)
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. (2010) (40)
Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). (2011) (39)
2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. (2021) (38)
Knowledge Deficits Related to the QT Interval Could Affect Patient Safety (2003) (38)
Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. (2016) (37)
Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry). (2014) (37)
A survey of health care practitioners’ knowledge of the QT interval (2005) (37)
Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age. (2010) (37)
Placebo-Controls in Short-Term Clinical Trials of Hypertension (2001) (37)
Incidence and Predictors of Sudden Cardiac Death in Patients with Diastolic Heart Failure (2007) (36)
Reperfusion ventricular arrhythmia 'bursts' in TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction: a more precise definition of reperfusion arrhythmias. (2008) (35)
Is Cardiac Resynchronization Therapy an Antiarrhythmic Therapy for Atrial Fibrillation? A Systematic Review and Meta-Analysis (2013) (34)
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing☆☆☆ (2016) (34)
Follow-up of Patients With New Cardiovascular Implantable Electronic Devices: Are Experts’ Recommendations Implemented in Routine Clinical Practice? (2013) (34)
Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry. (2021) (34)
Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a Collaborative Pan-Stakeholder Critical Path Registry Model: a Cardiac Safety Research Consortium "Incubator" Think Tank. (2010) (34)
Multiple Comorbidities and Response to Cardiac Resynchronization Therapy: MADIT-CRT Long-Term Follow-Up. (2017) (33)
Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure (2020) (33)
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. (2008) (33)
Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial (2018) (32)
Predictors of an inadequate defibrillation safety margin at ICD implantation: insights from the National Cardiovascular Data Registry. (2014) (32)
Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry (2018) (32)
Recent Innovations, Modifications, and Evolution of ACC/AHA Clinical Practice Guidelines: An Update for Our Constituencies: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2019) (31)
Left Atrial Appendage Electrical Isolation for Treatment of Recurrent Atrial Fibrillation: A Meta-Analysis. (2017) (31)
Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. (2014) (31)
Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women (2016) (30)
New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials (2017) (30)
Usefulness of the Duke Sudden Cardiac Death risk score for predicting sudden cardiac death in patients with angiographic (>75% narrowing) coronary artery disease. (2009) (29)
Defibrillators: Selecting the Right Device for the Right Patient (2016) (29)
Research Priorities in Atrial Fibrillation Screening: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. (2021) (29)
Patient, Physician, and Procedural Factors Influencing the Use of Defibrillation Testing during Initial Implantable Cardioverter Defibrillator Insertion: Findings from the NCDR® (2013) (29)
Sudden cardiac death in patients with myocarditis: Evaluation, risk stratification, and management. (2019) (29)
The subcutaneous implantable cardioverter-defibrillator in review. (2019) (28)
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial (2010) (28)
Association Between a Prolonged PR Interval and Outcomes of Cardiac Resynchronization Therapy: A Report From the National Cardiovascular Data Registry. (2016) (28)
Primary prevention implantable cardioverter-defibrillators and survival in older women. (2015) (28)
2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. (2017) (27)
Patient preference in the decision to place implantable cardioverter-defibrillators. (2012) (27)
Is Rhythm‐Control Superior to Rate‐Control in Patients with Atrial Fibrillation and Diastolic Heart Failure? (2010) (26)
Educational videos to reduce racial disparities in ICD therapy via innovative designs (VIVID): a randomized clinical trial. (2013) (26)
Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. (2015) (26)
Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. (2016) (25)
Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. (2012) (25)
Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes (2017) (24)
Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease. (2015) (24)
Comparative Effectiveness of Cardiac Resynchronization Therapy With an Implantable Cardioverter-Defibrillator Versus Defibrillator Therapy Alone (2014) (23)
Outcomes 1 Year After Implantable Cardioverter-Defibrillator Lead Abandonment Versus Explantation for Unused or Malfunctioning Leads: A Report from the National Cardiovascular Data Registry. (2016) (22)
HRS White Paper on interoperability of data from cardiovascular implantable electronic devices (CIEDs). (2019) (22)
Ethical responsibilities toward indirect and collateral participants in pragmatic clinical trials (2015) (22)
Implantable cardioverter‐defibrillators in heart failure patients with reduced ejection fraction and diabetes (2018) (22)
Implications of ventricular arrhythmia “bursts” with normal epicardial flow, myocardial blush, and ST-segment recovery in anterior ST-elevation myocardial infarction reperfusion: A biosignature of direct myocellular injury “downstream of downstream” (2015) (22)
Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND‐HF (2018) (22)
Dofetilide dose reductions and discontinuations in women compared with men. (2018) (22)
The Food and Drug Administration and pragmatic clinical trials of marketed medical products (2015) (22)
Follow-up of patients with new cardiovascular implantable electronic devices: is adherence to the experts' recommendations associated with improved outcomes? (2013) (21)
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary. (2020) (21)
Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies. (2010) (21)
Predicting appropriate shocks in patients with heart failure: Patient level meta‐analysis from SCD‐HeFT and MADIT II (2016) (20)
Are racial/ethnic gaps in the use of cardiac resynchronization therapy narrowing?: an analysis of 107,096 patients from the National Cardiovascular Data Registry's ICD Registry. (2012) (20)
Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation. (2014) (20)
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. (2016) (19)
Single vs. dual chamber implantable cardioverter-defibrillators or programming of implantable cardioverter-defibrillators in patients without a bradycardia pacing indication: systematic review and meta-analysis (2018) (19)
Catheter ablation of ventricular tachycardia: Lessons learned from past clinical trials and implications for future clinical trials. (2016) (19)
Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial (2017) (19)
Survey of current perspectives on consumer-available digital health devices for detecting atrial fibrillation (2020) (19)
Sex Differences in Heart Failure. (2021) (18)
Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial (2019) (17)
'Real-world' observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). (2019) (17)
Measuring quality in electrophysiology (2016) (17)
Developing the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a collaborative pan-stakeholder critical path registry model: a Cardiac Safety Research Consortium "Incubator" Think Tank. (2010) (16)
Regional variations in physicians' attitudes and recommendations surrounding implantable cardioverter-defibrillators. (2011) (16)
Clinical Effectiveness of Cardiac Resynchronization Therapy Versus Medical Therapy Alone Among Patients With Heart Failure (2014) (16)
Catheter ablation for ventricular tachycardia (VT) in patients with ischemic heart disease: a systematic review and a meta-analysis of randomized controlled trials (2016) (16)
Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: a systematic review. (2014) (16)
Recent Innovations, Modifications, and Evolution of ACC/AHA Clinical Practice Guidelines: An Update for Our Constituencies: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2019) (16)
Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy. (2007) (16)
One‐year mortality after implantable cardioverter‐defibrillator placement within the Veterans Affairs Health System (2020) (16)
Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. (2013) (16)
Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials (2019) (16)
Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. (2013) (16)
Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention: From the NCDR ICD Registry. (2017) (16)
Efficacy and Safety of Apixaban in Patients Following Cardioversion for Atrial Fibrillation: Insights from the ARISTOTLE trial (2013) (15)
Complications Involving the Subcutaneous Implantable Cardioverter Defibrillator: Lessons Learned from MAUDE. (2020) (15)
The Association of Duration of participation in get with the guidelines‐resuscitation with quality of Care for in‐Hospital Cardiac Arrest (2018) (15)
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. (2014) (15)
Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention (2015) (14)
Exploring patient–provider decision-making for use of anticoagulation for stroke prevention in atrial fibrillation: Results of the INFORM-AF study (2018) (14)
Transparent sharing of digital health data: A call to action. (2019) (14)
Apixaban and warfarin are associated with a low risk of stroke following cardioversion for atrial fibrillation : results from the ARISTOTLE Trial (2012) (14)
Do Physicians’ Attitudes toward Implantable Cardioverter Defibrillator Therapy Vary by Patient Age, Gender, or Race? (2011) (14)
Performance measures to promote quality improvement in sudden cardiac arrest prevention and treatment. (2013) (14)
Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation (2018) (14)
Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement: An Analysis From the NCDR ICD Registry. (2017) (14)
Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital. (2008) (14)
Changes in the digital health landscape in cardiac electrophysiology: A pre-and peri-pandemic COVID-19 era survey (2020) (14)
Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). (2019) (13)
Outcomes Associated With Warfarin Use in Older Patients With Heart Failure and Atrial Fibrillation and a Cardiovascular Implantable Electronic Device: Findings From the ADHERE Registry Linked to Medicare Claims (2012) (13)
Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction (2015) (13)
Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines‐Atrial Fibrillation (2020) (12)
Catheter Ablation for Treatment of Atrial Fibrillation (2015) (12)
Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation (2019) (12)
Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy. (2011) (12)
Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure) (2017) (12)
Highlights from the American College of Cardiology 48th Annual Scientific Sessions: March 7 to 10, 1999. (1999) (12)
Future Research Prioritization: Implantable Cardioverter-Defibrillator Therapy in Older Patients (2015) (11)
Age Differences in the Use of Implantable Cardioverter‐Defibrillators Among Older Patients Hospitalized with Heart Failure (2013) (11)
FDA-Catalyst—Using FDA’s Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial (2018) (11)
Quality of care for sudden cardiac arrest: Proposed steps to improve the translation of evidence into practice. (2011) (11)
Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report (2021) (11)
Outcomes for Hemodialysis Patients Given Cardiopulmonary Resuscitation for Cardiac Arrest at Outpatient Dialysis Clinics. (2019) (11)
Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. (2013) (11)
Stellate Ganglion Blockade: an Intervention for the Management of Ventricular Arrhythmias (2020) (11)
Highlights from the American Heart Association 72nd Scientific Sessions: November 6 to 10, 1999 (2000) (11)
Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients (2015) (10)
Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib). (2020) (10)
2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards) and the American Society of Ec (2019) (10)
Temporal Trends in and Factors Associated With Use of Single- Versus Dual-Coil Implantable Cardioverter-Defibrillator Leads: Data From the NCDR ICD Registry. (2017) (10)
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias (2020) (10)
Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of Predicted INR Control for Stroke Prevention in Atrial Fibrillation (2013) (10)
When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion? (2018) (10)
A case of severe ischemia‐induced QT prolongation (2001) (9)
Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry (2018) (9)
Relation between time from myocardial infarction to enrolment and patient outcomes in the Multicenter UnSustained Tachycardia Trial. (2010) (9)
APIXABAN IS EFFICACIOUS AND SAFE IN PATIENTS WITH ATRIAL FIBRILLATION USING CONCOMITANT AMIODARONE: AN ANALYSIS FROM THE ARISTOTLE TRIAL (2013) (9)
Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry. (2016) (9)
Same-day discharge and risks of mortality and readmission after elective ICD placement for primary prevention. (2015) (9)
Apixaban to prevent stroke in patients with atrial fibrillation: a review (2017) (9)
Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. (2017) (9)
Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation (2014) (8)
Future research prioritization in cardiac resynchronization therapy. (2020) (8)
Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. (2017) (8)
2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (2017) (8)
Optimal Timing of Implantable Cardioverter‐Defibrillator Implantation After Myocardial Infarction: A Decision Analysis (2010) (8)
Racial and Ethnic Differences in the Management of Atrial Fibrillation (2021) (8)
Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: A systematic review (2020) (8)
Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. (2014) (8)
A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE (2013) (8)
Optimizing mechanically sensed atrial tracking in patients with atrioventricular-synchronous leadless pacemakers: A single-center experience (2021) (7)
Decision‐making regarding primary prevention implantable cardioverter‐defibrillators among older adults (2019) (7)
Physicians’ perceptions of shared decision‐making for implantable cardioverter‐defibrillators: Results of a physician survey (2019) (7)
Predicting atrial fibrillation recurrence after ablation in patients with heart failure: Validity of the APPLE and CAAP‐AF risk scoring systems (2019) (7)
Coverage with evidence development: where are we now? (2019) (7)
Medications That Prolong the QT Interval (2003) (7)
Comparisons of Hospitalization Rates Among Younger Atrial Fibrillation Patients Receiving Different Antiarrhythmic Drugs (2015) (7)
Assessment of the quality of existing patient educational tools focused on sudden cardiac arrest: a systematic evaluation by the Sudden Cardiac Arrest Thought Leadership Alliance (2013) (7)
Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet). (2016) (7)
AHA / ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death (7)
Stroke prevention in atrial fibrillation: Closing the gap (2019) (7)
Association Between a Prolonged PR Interval and Outcomes of Cardiac Resynchronization TherapyClinical Perspective (2016) (7)
Catheter ablation of atrial fibrillation in patients with diabetes mellitus (2020) (7)
Leadless pacemaker implantation after lead extraction for cardiac implanted electronic device infection (2022) (7)
Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial FibrillationCLINICAL PERSPECTIVE (2016) (6)
Complications from prophylactic replacement of cardiac implantable electronic device generators in response to United States Food and Drug Administration recall: A systematic review and meta-analysis. (2015) (6)
Angiotensin-converting enzyme inhibitors: a new therapy for atrial fibrillation? (2004) (6)
Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update (2018) (6)
Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator? (2014) (6)
Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation (2020) (6)
Longitudinal Outcomes of Subcutaneous or Transvenous Implantable Cardioverter-Defibrillators in Older Patients. (2022) (6)
Abstract 2428: Patients Who Receive an Implantable Cardioverter Defibrillator for MADIT-II Criteria in Clinical Practice are Different From Patients Enrolled in MADIT-II (2007) (6)
Treatment of Older Patients with Atrial Fibrillation by Morbidity Burden. (2020) (6)
Trends in Use and In-Hospital Outcomes of Subcutaneous Implantable Cardioverter Defibrillators in Patients Undergoing Long-Term Dialysis. (2020) (6)
Associations Between Anticoagulation Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Atrial Fibrillation (2014) (5)
A Pilot Study Using an Implantable Device to Characterize Cardiac Arrhythmias in Hemodialysis Patients: Implications for Future Research (2012) (5)
Arrhythmias in Female Patients: Incidence, Presentation and Management. (2022) (5)
Use Of Rate And Rhythm Control Drugs In Patients Younger Than 65 Years With Atrial Fibrillation. (2014) (5)
Deficits in knowledge related to the QT interval that could impact patient safety (2002) (5)
Analysis of Respiratory Fluoroquinolones and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis. (2021) (5)
Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis. (2020) (5)
The relationship between baseline and follow‐up left ventricular ejection fraction with adverse events among primary prevention ICD patients (2018) (5)
Sudden Cardiac Death in Patients with Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results from the Surgical Treatment for Ischemic Heart Failure (STICH) Randomized Clinical Trial (2017) (5)
HRS White Paper on Clinical Utilization of Digital Health Technology (2021) (5)
Effectiveness of catheter ablation of atrial fibrillation according to heart failure etiology (2020) (5)
SURVIVAL BENEFIT OF THE PRIMARY PREVENTION IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR AMONG OLDER PATIENTS: DOES AGE MATTER? A PATIENT-LEVEL META-ANALYSIS OF 5 CLINICAL TRIALS (2014) (4)
Changes in Intrathoracic Fluid Index predict subsequent adverse events: Results of the Multi-site Program to Access and Review Trending INformation and Evaluate CoRrelation to Symptoms in Patients with Heart Failure (PARTNERS HF) Trial (2008) (4)
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary (2020) (4)
Azithromycin use increases the risk of sudden cardiac death in patients with hemodialysis-dependent kidney failure. (2022) (4)
How well does early‐career investigators’ cardiovascular outcomes research training align with funded outcomes research? (2017) (4)
Abstract 2015: Sudden Cardiac Death in Patients with Diastolic Heart Failure (2006) (4)
Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. (2020) (4)
Does ICD Therapy Benefit Women with a History of Myocardial Infarction and Severe Left Ventricular Dysfunction? (2005) (4)
Ongoing Management of Patients With Supraventricular Tachycardia. (2016) (4)
Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes (2018) (4)
Inappropriate shocks in a patient with a subcutaneous implantable cardioverter-defibrillator (2016) (3)
Use of β-Blockers in Patients with an Implantable Cardioverter Defibrillator (2009) (3)
EARLY USE OF THE SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IN THE UNITED STATES: A REPORT FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY (2016) (3)
Fourth Annual Go Red for Women Issue. (2020) (3)
Videos to reduce racial disparities in ICD therapy Via Innovative Designs (VIVID) trial: Rational, design and methodology. (2019) (3)
Sudden Cardiac Death in Patients with Diastolic Heart Failure (2006) (3)
ICDs Are Still an Effective Therapy To Prevent Sudden Cardiac Death in Heart Failure. (2019) (3)
THE ROLE OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICDS) IN PATIENTS WITH A LEFT VENTRICULAR ASSIST DEVICE (LVAD): A SYSTEMATIC REVIEW AND META-ANALYSIS (2016) (3)
Knowledge and Insights Vested in Us by the VEST. (2018) (3)
Management of Ventricular Arrhythmias and Sudden Cardiac Death Risk Related to Ischemic and Nonischemic Cardiomyopathy. (2018) (3)
Epidemiology, evaluation, and management of conduction disturbances after transcatheter aortic valve replacement. (2021) (3)
Promise of Factor Xa Inhibition in Atrial Fibrillation (2012) (3)
Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation: Insights From the American Heart Association Get With The Guidelines–Atrial Fibrillation Program (2018) (3)
Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: Diminishing Returns With Advancing Age? (2017) (3)
Use Of Rate And Rhythm Control Drugs In Patients Younger Than 65 Years With Atrial Fibrillation. (2014) (3)
Medications That Prolong the QT Interval--Reply (2003) (3)
The Use of Implantable Cardioverter-defibrillators in the Prevention of Sudden Cardiac Death: A Focus on Congenital Heart Disease and Inherited Arrhythmia Syndromes (2017) (2)
Patients' willingness to participate in placebo-controlled trials of antihypertensive therapy. (2003) (2)
Abstract 3625: Do Patients Who Meet SCD-HeFT Criteria in Clinical Practice Differ from Patients Enrolled in SCD-HeFT? (2007) (2)
Management of Ventricular Arrhythmias and Sudden Cardiac Death Risk Associated With Cardiac Channelopathies. (2018) (2)
Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy (2021) (2)
Quality Assessment of Included Studies (2015) (2)
OptiVol for Volume Assessment in Patients With Continuous Flow Left Ventricular Assist Device. (2020) (2)
Management of pace-terminated ventricular arrhythmias. (2015) (2)
Quality improvement in heart rhythm care: the path forward (2013) (2)
Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes? (2018) (2)
Proceedings from Heart Rhythm Society's emerging technologies forum, Boston, MA, May 12, 2015. (2016) (2)
Abstract P108: Extent of and Reasons for Under-Utilization of Implantable Cardioverter Defibrillator Devices Among Eligible Patients With Left Ventricular Systolic Dysfunction in Clinical Practice (2011) (2)
Expert Consensus Statement on Pacemaker Device and Mode Selection Developed in partnership between the Heart Rhythm Society ( HRS ) and the American College of Cardiology Foundation ( ACCF ) and in collaboration with the Society of Thoracic Surgeons (2012) (2)
Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥ 65 Years of Age with a Low Ejection Fraction Following Coronary Revascularization. (2020) (2)
USE AND COMPARATIVE EFFECTIVENESS OF CARDIAC RESYNCHRONIZATION THERAPY AMONG PATIENTS WITH HEART FAILURE AND ATRIAL FIBRILLATION: DATA FROM THE NCDR® REGISTRY (2014) (2)
Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants (2022) (2)
Centers for Medicare and Medicaid Services' Decision to Reconsider Coverage Indications for ICDs: Where to Now? (2017) (2)
The Risk of Sudden Cardiac Death in Mitral Valve Prolapse: Are All Patients Created Equal? (2016) (2)
Implantable Cardioverter Defibrillators Have Stood the Test of Time! (2019) (2)
Atrial fibrillation in congestive heart failure: is rhythm control therapy superior to rate control therapy? (2003) (2)
Abstract 9039: Predictors of High Defibrillation Energy Requirements: Results From the NCDR ICD Registry (2012) (2)
Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". (2014) (2)
Amiodarone versus implantable cardioverter defibrillator for asymptomatic nonsustained ventricular tachycardia in nonischemic dilated cardiomyopathy. (2004) (2)
Digital health in electrophysiology and the COVID-19 global pandemic (2020) (2)
Acute Treatment of Patients With Supraventricular Tachycardia. (2016) (2)
Sex differences in left ventricular electrical dyssynchrony and outcomes with cardiac resynchronization therapy (2020) (2)
Sixth Annual Go Red for Women Issue. (2022) (2)
Complications and Mortality Following CRT-D Versus ICD Implants in Older Medicare Beneficiaries With Heart Failure. (2022) (2)
Emerging Implantable Device Technology for Patients at the Intersection of Electrophysiology and Heart Failure Interdisciplinary Care. (2021) (2)
Risk Stratification of Individuals with the Brugada Electrocardiogram: A Myth or a Reality? (2006) (2)
Abstract 3233: Cost-Effectiveness of the Implantable Cardioverter Defibrillator in the Elderly (2008) (1)
Response to letter regarding article, “sustained ventricular tachycardia and ventricular fibrillation complicating non–ST-segment elevation acute coronary syndromes”. (2013) (1)
Resuscitation Science in Circulation: A Timely Topic. (2016) (1)
Erratum to ‘2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-deﬁbrillator programming and testing’ [Journal of Arrhythmia 32/1 (2016) 1–28] (2016) (1)
Perplexing Results From the PRAETORIAN Trial: Revisiting the Debate About the Value of Antitachycardia Pacing. (2022) (1)
Third Annual Go Red for Women Issue. (2019) (1)
Be-All End-All Real-World Evidence on the Subcutaneous ICD. (2021) (1)
THE ROLE OF BASELINE VERSUS LONG-TERM FOLLOW-UP EJECTION FRACTION IN PREDICTING ADVERSE EVENTS AMONG PRIMARY PREVENTION IMPLANTABLE CARDIOVERTER DEFIBRILLATOR RECIPIENTS (2017) (1)
Proton pump inhibitors may enhance the risk of citalopram‐ and escitalopram‐associated sudden cardiac death among patients receiving hemodialysis (2022) (1)
Periprocedural Risk and Survival after ICD Placement in Patients with Advanced Heart Failure (2018) (1)
Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. (2017) (1)
Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program". (2017) (1)
QT-Prolonging Antibiotics, Serum-to-Dialysate Potassium Gradient, and Risk of Sudden Cardiac Death Among Patients Receiving Maintenance Hemodialysis (2023) (1)
, Among Patients With Heart Failure and Atrial Fibrillation Associations Between Anticoagulation Therapy and Risks of Mortality and Readmission (1)
Abstract 16: Low Rates of Implantable Cardioverter-Defibrillator Use Among Medicare Patients with Low Ejection Fraction After Myocardial Infarction (2014) (1)
Toward more optimal use of primary prevention implantable cardioverter-defibrillators: how do we get there? (2011) (1)
Sudden Cardiac Arrest Meeting the Challenge (2011) (1)
Abstract 223: Outcomes of Older Patients Receiving Secondary Prevention Implantable Cardioverter Defibrillators: An Analysis From the NCDR ICD Registry (2015) (1)
Outcomes for Patients with Anterior Myocardial Infarction and Prior Cardiac Arrest in the Home Automated External Defibrillator Trial (HAT). (2021) (1)
Are the results of the multicenter automatic defibrillator implantation trial-II applicable to patients seen at a tertiary referral center? (2003) (1)
The changing epidemiology of ventricular arrhythmias and sudden cardiac death: Is it a reality? (2019) (1)
Factors and outcomes associated with improved left ventricular systolic function in patients with cardiomyopathy (2020) (1)
Response to letter regarding article, "Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry". (2015) (1)
Cardiac Resynchronization Therapy in the Autumn of Life. (2015) (1)
EFFICACY AND SAFETY OF APIXABAN COMPARED WITH WARFARIN ACCORDING TO CHADS2 AND HASBLED RISK SCORES FOR STROKE PREVENTION IN ATRIAL FIBRILLATION (2012) (1)
Implantable Cardioverter-Defibrillators in Patients With Left Ventricular Assist Devices: On Trial and in Need of a Trial. (2017) (1)
Comparative Effectiveness of Primary Prevention Implantable Cardioverter‐Defibrillators in Older Heart Failure Patients With Diabetes Mellitus (2020) (1)
Implantable Cardioverter-Defibrillator Use AmongMedicare PatientsWith Low Ejection Fraction After AcuteMyocardial Infarction (2015) (1)
Abstract 322: SPECT Myocardial Perfusion Imaging and the Risk of Sudden Cardiac Death in Patients With Coronary Disease and Left Ventricular Ejection Fraction >35% (2009) (1)
Transforming Atrial Fibrillation Research to Integrate Social Determinants of Health: A National Heart, Lung, and Blood Institute Workshop Report. (2022) (1)
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. (2021) (1)
Anticoagulation after Ablation for Atrial Fibrillation. (2021) (1)
Abstract 15975: Multimorbidity is Associated With Greater Risk of Thromboembolism and Bleeding in Patients With Atrial Fibrillation but a Constant Benefit of Apixaban: Results From ARISTOTLE (2017) (1)
Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop (2023) (1)
Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. (2022) (1)
1096-71 A national survey of health care practitioners' knowledge of the QT interval (2004) (0)
Outcomes Associated With Subcutaneous Implantable Cardioverter Defibrillators-Reply. (2017) (0)
Table H6, Catheter details, mapping information and ablation approaches used in included studies (2015) (0)
Sample Data Extraction Forms (2015) (0)
From the American Heart Association American Heart Association Atrial Fibrillation Research Summit: A Conference Report (2013) (0)
Cardiac resynchronization therapy outcomes with left ventricular lead concordant with latest mechanical activation: A meta‐analysis (2022) (0)
Regulation Without Representation: Cardiac Device Patient Knowledge and Attitudes about the FDA Regulatory Process. (2020) (0)
Table 14, Strength of evidence domains for antiarrhythmic drugs versus electrical cardioversion (2013) (0)
Response by Friedman and Al-Khatib to Letter Regarding Article, "Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry". (2018) (0)
Figure 14, Forest plot of maintenance of sinus rhythm for transcatheter PVI with or without CFAE ablation (2013) (0)
Response to Letter Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women". (2016) (0)
Abstract 2032: Mechanistic and Prognostic Implications of "Burst" Ventricular Arrhythmias and Their Precise Timing after TIMI 3 Reperfusion in Anterior ST Elevation Myocardial Infarction (2007) (0)
Aha Conference Proceedings American Heart Association Atrial Fibrillation Research Summit a Conference Report from the American Heart Association Mechanisms of Af: Basic and Translational Science and Genetics (2011) (0)
List of Excluded Studies With Rationale (2015) (0)
The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study. (2022) (0)
Medications Are Important for Sudden Cardiac Death Prevention But So Is the Implantable Cardioverter-Defibrillator. (2020) (0)
Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs (2017) (0)
Reply: Complications and Mortality Following CRT-D vs ICD. (2022) (0)
Outcomes with Apixaban by Type of AF (2012) (0)
Abstract 9920: Outcomes Associated With Lead Abandonment versus Lead Extraction Strategies for Revision of Sterile Leads: An NCDR® Analysis (2015) (0)
Table A, Summary of strength of evidence (SOE) and effect estimate for KQ 1a (2013) (0)
Predictors and long-term mortality of atrioventricular block after acute myocardial infarction treated with thrombolysis (2003) (0)
Table F3, Study Quality Ratings of the Included RCT Comparing Cryoballoon Ablation with Medical Therapy with a Mixed Population of Patients with Atrial Fibrillation (2015) (0)
ARE THERE DIFFERENCES IN IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR COUNSELING RATES AMONG ELIGIBLE PATIENTS HOSPITALIZED FOR HEART FAILURE? NATIONAL RESULTS FROM THE AMERICAN HEART ASSOCIATION’S GET WITH THE GUIDELINES- HEART FAILURE PROGRAM (2015) (0)
Table 5, Ventricular rate achieved (2013) (0)
Abstract P207: What is More Important in Cardiologists' Decision Making Around Implantable-Cardioverter Defibrillators (ICD), Mortality Data or Patient Preferences? (2011) (0)
Implantable Defibrillators for Primary Prevention of Sudden Death in Patients on Dialysis. (2019) (0)
Response to: The paradox of implantable cardioverter-defibrillator: When guidelines play against care improvement. (2021) (0)
Table 6, Strength of evidence domains for strict versus lenient rate-control strategies (2013) (0)
Figure 26, Forest plot of bleeding events for rate- versus rhythm-control strategies (2013) (0)
Table 15, Studies including comparisons of pharmacological agents (2013) (0)
Khatib Cardioverter-Defibrillators : How Do We Get There ? Toward More Optimal Use of Primary Prevention Implantable (2011) (0)
Reply: The Benefit of Cardiac Resynchronization Therapy Is Not Hindered by the Number of Comorbidities. (2017) (0)
APIXABAN VERSUS WARFARIN FOR PATIENTS WITH RECENT ONSET ATRIAL FIBRILLATION: INSIGHTS FROM THE ARISTOTLE TRIAL (2016) (0)
MY APPROACH to the risk stratification of patients for sudden cardiac death. (2017) (0)
P5793Faster heart rate is associated with significantly higher risk of death and hospitalization due to heart failure in patients with persistent or permanent atrial fibrillation: insights from ARISTOTLE (2018) (0)
Appropriateness of Mapping and Imaging Modalities in Interventional Electrophysiology (2019) (0)
Table 12, Comparisons of antiarrhythmic drugs for restoration of sinus rhythm (2013) (0)
Key to Included Primary and Companion Articles (2013) (0)
3153Rate versus rhythm control and mortality in atrial fibrillation patients: a Danish nationwide cohort study (2019) (0)
Utilization of Implantable Cardioverter Defibrillators Among Patients with a Left Ventricular Assist Device: Insights From a National Database. (2022) (0)
arfarin Use and Outcomes in Patients with Atrial ibrillation Complicating Acute Coronary Syndromes (0)
CONTEMPORARY PATTERNS OF PRACTICE AND CHARACTERISTICS OF PATIENTS UNDERGOING DEFIBRILLATION TESTING VERSUS THOSE WHO DO NOT UNDERGO TESTING AT THE TIME OF INITIAL IMPLANTABLE CARDIOVERTER IMPLANTATION: ANALYSIS OF THE NCDR ICD REGISTRY (2012) (0)
Error in Conflicts of Interest Disclosures. (2017) (0)
Table C, Key findings and strength of evidence for Key Question 1: Short-term (≤12 months) efficacy and effectiveness outcomes comparing cryoballoon ablation with medical therapy for AF (2015) (0)
Antero-lateral vs. antero-posterior electrode position for cardioversion of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. (2023) (0)
Better survival for victims of cardiac arrest occurring in sports facilities: From speculations to facts. (2015) (0)
Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation : Findings From the NCDR ICD Registry (2016) (0)
Fifth Annual Go Red for Women Issue. (2020) (0)
Authors' Reply. (2019) (0)
Abstract 17244: Is Selection of Antiarrhythmic Drugs for Atrial Fibrillation Consistent with Guideline Recommendations: Results from a Large Contemporary Community Cohort (2012) (0)
Abstract P74: Regional Variations in Physicians' Attitudes Towards Implantable Cardioverter-Defibrillators (2011) (0)
Abstract 1519: Atrial Fibrillation Is Independently Associated With A High Risk of Death in Patients With Acute Coronary Syndromes (2007) (0)
Digoxina y mortalidad en pacientes con fibrilación auricular (2018) (0)
Abstract 12202: New York Heart Association Class and the Mortality Benefit From Primary Prevention Implantable Cardioverter Defibrillator Use: A Pooled Analysis of 4 Randomized Control Trials (2016) (0)
Abstract 16620: The Prognostic Value of Mechanical Dyssynchrony Measured by GSPECT MPI versus Electrical Dyssnchrony Measured by QRS Duration Among Patients With an Ejection Fraction >35% (2014) (0)
Table 17, Studies assessing recurrence of AF (2013) (0)
Abstract 13344: Is Cardiac Resynchronization Therapy Use Improving Among Racial/Ethnic Minorities? An Analysis of 107,096 Patients from the NCDR-ICD Registry (2011) (0)
Table F5, Study Quality Ratings of Included Observational Studies Comparing Radiofrequency Catheter Ablation with Cryoballoon Ablation in Patients with Paroxysmal or Persistent Atrial Fibrillation (2015) (0)
Temporal Trends in and Factors Associated With Use of Single- Versus Dual-Coil Implantable Cardioverter-De ﬁ brillator Leads (2017) (0)
Table F, Summary of strength of evidence and effect estimate for KQ 5—procedural rhythm-control therapies (2013) (0)
SPECT myocardial perfusion imaging is a strong predictor of sudden cardiac death in patients with coronary artery disease (2008) (0)
Description of Outcomes Measures, Devices, and Ongoing Trials, and Additional Results Tables (2015) (0)
Figure 25, Forest plot of mixed embolic events for rate- versus rhythm-control strategies (2013) (0)
ICD Implantation and Evidence-Based Patient Selection—Reply (2011) (0)
Abstract 13963: Type 2 Myocardial Infarction: Incidence, Risk Factors, and Outcomes Among 41,581 Patients Enrolled in 3 Large Randomized Clinical Trials (2019) (0)
Table 20, Strength of evidence domains for rhythm-control procedures (2013) (0)
INCIDENCE AND PREDICTORS OF SUDDEN CARDIAC DEATH AFTER HOSPITALIZATION FOR NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: AN ANALYSIS FROM THE TRACER TRIAL (2013) (0)
Abstract 19675: Testing Strategies and Poor Outcomes of Syncope among Medicare Beneficiaries (2014) (0)
Abstract 229: Training Cardiovascular Outcomes Researchers: A Survey of Mentees and Mentors (2015) (0)
Abstract 14391: Mechanical Dyssynchrony Defined by Phase Analysis from GSPECT: Does it Predict Mortality? (2012) (0)
Table 18, Studies reporting all-cause mortality as an outcome (2013) (0)
Table G, Summary of strength of evidence and effect estimate for KQ 5—pharmacological rhythm-control therapies (2013) (0)
Personalizing Risk Assessment for Sudden Cardiac Death in Heart Failure: A Dream or a Reality? (2023) (0)
Figure 22, Forest plot of cardiovascular hospitalizations for rate- versus rhythm-control strategies (2013) (0)
Atrial fibrillation and kidney disease: stuck outside the CABANA. (2019) (0)
Implantable Cardioverter Defibrillators for Nonischemic Cardiomyopathy-Reply. (2017) (0)
Abstract 3595: Amiodarone Use After Acute Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Is Associated with Excess Mortality (2006) (0)
Figure D, Overview of procedural treatment comparisons evaluated for KQ 5 (2013) (0)
Outcomes of Cardiac Resynchronization Therapy with Image-Guided Left Ventricular Lead Placement at the Site of Latest Mechanical Activation: A Systematic Review and Meta-Analysis (2022) (0)
Table H, Key findings and strength of evidence for Key Question 2: Comparative short-term and long-term complications and harms associated with cryoballoon ablation versus RFA for AF (2015) (0)
COMPARATIVE EFFECTIVENESS OF CARDIAC RESYNCHRONIZATION THERAPY WITH DEFIBRILLATOR VERSUS DEFIBRILLATOR ALONE IN HEART FAILURE PATIENTS WITH MODERATE TO SEVERE CHRONIC KIDNEY DISEASE (2015) (0)
Emerging topics in electrophysiology. (2021) (0)
Abstract 19621: Sudden Cardiac Death in Patients with Ischemic Heart Failure Undergoing CABG: Results from the STICH trial (2014) (0)
Table 4, Strength of evidence domains for rate-control drugs (2013) (0)
Cardiac resynchronization therapy in patients with a history of atrial fibrillation: insights from five major clinical trials (2022) (0)
Abstract 19011: Predictors of Performing Defibrillation Testing Among Patients Implanted With a Subcutaneous Implantable Cardioverter Defibrillator: A Report From the National Cardiovascular Data Registry (2017) (0)
Abstract 2866: Factors Associated with Rhythm versus Rate Control Strategies in Hospitalized Patients with Atrial Fibrillation (2007) (0)
UNDETERMINED CAUSE OF DEATH: A POOLED ANALYSIS OF 9,307 DEATHS ACROSS 9 CARDIOVASCULAR TRIALS (2018) (0)
Table F1, Study Quality Ratings of Included RCTs Comparing Radiofrequency Catheter Ablation Versus Medical Therapy in Patients with Paroxysmal or Persistent Atrial Fibrillation (2015) (0)
Table H4, Adverse events for case series evaluating catheter ablation for the treatment of AF (2015) (0)
Association Of Comorbidities With Clinical Outcomes Of Cardiac Resynchronization Therapy: A Meta-analysis Of Patient-level Data From Eight Major Clinical Trials (2023) (0)
OUTCOMES ASSOCIATED WITH SAME-DAY DISCHARGE AFTER ELECTIVE PLACEMENT OF A PRIMARY PREVENTION IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR AMONG OLDER PATIENTS (2014) (0)
RECALLED ICD GENERATORS IN THE NCDR-ICD REGISTRY: OUTCOMES AND SURVEILLANCE IMPLICATIONS (2019) (0)
Table H8, Ongoing clinical trials (2015) (0)
Sex Differences in Sustained Ventricular Arrhythmias: A Continuing Dialogue. (2022) (0)
JAMA Peer Reviewers in 2004 (2016) (0)
JAMA Peer Reviewers in 2018. (2019) (0)
Helping Black Patients Decide on a Treatment for Chronic Heart Failure -- The VIVID Study (2022) (0)
Report Addendum (Submitted June 13, 2014) (2013) (0)
Abstract 12: Accuracy and Validation of an Automated Electronic Medical Record Algorithm to Identify Patients with Atrial Fibrillation at Risk for Stroke (2014) (0)
Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis. (2021) (0)
Figure 19, Forest plot of maintenance of sinus rhythm for rate- versus rhythm-control strategies (2013) (0)
Mechanical dyssynchrony defined by phase analysis from GSPECT:Does it predict all cause and cardiovascular mortality? (2013) (0)
Abstract 18707: Do Patients with Heart Failure and Atrial Fibrillation Adhere to Warfarin After Hospital Discharge? Findings from the Get With The Guidelines-Heart Failure Registry and Medicare Linked Database (2012) (0)
INFLUENCE OF CHRONIC KIDNEY DISEASE ON THE EFFICACY OF PRIMARY PREVENTION IMPLANTABLE CARDIOVERTER DEFIBRILLATORS: A META-ANALYSIS OF THREE RANDOMIZED TRIALS (2013) (0)
Predictable And SuStainable Implementation Of National Cardiovascular Registries Infrastructure: A Think Tank Report from MDEpiNet (2015) (0)
letter to the editor. (2022) (0)
Seventh Annual Go Red for Women Issue. (2023) (0)
Figure A, Analytic framework for catheter ablation for atrial fibrillation (2015) (0)
Primary prevention implantable cardioverter defibrillators in women: More questions than answers. (2015) (0)
The role of atrial fibrillation catheter ablation in patients with heart failure. (2021) (0)
Table D, Summary of strength of evidence and effect estimate for KQ 3—one rate-control procedure versus another (2013) (0)
Figure 12, Forest plot of maintenance of sinus rhythm for PVI versus drug therapy (2013) (0)
Opportunities and challenges in heart rhythm research: Rationale and development of an electrophysiology collaboratory (2022) (0)
Table H2, SF-36 domain scores from RCTs comparing RF ablation with medical therapy for the treatment of AF (2015) (0)
The impact of implanting cardioverter-defibrillators in patients who meet the multicenter automatic defibrillator implantation trial-II criteria on the health care system at a tertiary referral center (2003) (0)
Is amiodarone associated with a higher risk of death in patients with advanced congestive heart failure (2005) (0)
Figure 16, Forest plot of all-cause mortality for Maze procedure versus standard of care (mitral valve surgery) (2013) (0)
Primary prevention implantable cardioverter defibrillators are effective in preventing overall mortality in older patients (2015) (0)
Treating Medicare Beneficiaries Cardioverter-Defibrillator Implantation Procedures Performed by Physicians The Relation Between Patients' Outcomes and the Volume of (2005) (0)
Table 9, Strength of evidence domains for one rate-control procedure versus another (2013) (0)
Abstract 14961: Predictors of an Insufficient Defibrillation Testing Safety Margin Among Patients Implanted With a Subcutaneous Implantable Cardioverter Defibrillator: A Report From the National Cardiovascular Data Registry (2017) (0)
Abstract 17304: Sudden Cardiac Death After Acute Heart Failure Hospitalization: Insights From ASCEND-HF (2015) (0)
Table H7, Study definitions of AF Recurrence and study reported techniques for monitoring recurrences (2015) (0)
Table G, Key findings and strength of evidence for Key Question 2: Comparative short-term and long-term complications and harms associated with cryoballoon ablation versus medical therapy for AF (2015) (0)
Do Implantable Cardioverter-Defibrillators Lower the Risk of Sudden Death and Total Mortality in Patients with End-Stage Renal Disease? (2017) (0)
Coronary heart disease Reperfusion ventricular arrhythmia ‘ bursts ’ predict larger infarct size despite TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction (2009) (0)
Table H3, SF-36 domain scores from comparative observational studies comparing RF ablation with medical therapy for the treatment of AF (2015) (0)
BENEFIT OF CARDIAC RESYNCHRONIZATION THERAPY AMONG OLDER PATIENTS: A PATIENT-LEVEL META-ANALYSIS (2023) (0)
When to implant an ICD following a myocardial infarction? (2013) (0)
Figure 4, Overview of treatment comparisons evaluated for KQ 1 (2013) (0)
Implantable Defibrillator Have We Learned (2011) (0)
Table H1, Descriptions and Scoring Details for Health Related Quality of Life Measures used in Included Studies (2015) (0)
Table 21, Strength of evidence domains for pharmacological rhythm-control therapies (2013) (0)
ARE PHYSICIANS LESS LIKELY TO OFFER AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR TO WOMEN, RACIAL MINORITIES, AND OLDER PATIENTS? (2010) (0)
P4774Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study (2019) (0)
Advances in Arrhythmia Management: Novel AF Therapies and Appropriate Device Use (2014) (0)
Figure 18, Forest plot of maintenance of sinus rhythm for PVI at the time of cardiac surgery versus cardiac surgery alone or in combination with antiarrhythmic drugs or catheter ablation (2013) (0)
New directions in clinical outcomes assessment (2011) (0)
Abstract 8844: 10-Year Mortality is Very High, and Warfarin Use Very Low, in Patients with Myocardial Infarction and Atrial Fibrillation (2011) (0)
Abstract 122: Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Adults With Diabetes Mellitus: Insights From the Get With the Guidelines - Heart Failure Registry (2018) (0)
TEMPORAL TRENDS IN AND FACTORS ASSOCIATED WITH SINGLE VERSUS DUAL COIL IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR LEADS: DATA FROM THE NCDR ICD REGISTRY (2015) (0)
Feasibility of a Randomized Clinical Trial of Cardiac Resynchronization Therapy With or Without an Implantable Defibrillator in Older Patients. (2022) (0)
Abstract 13591: Cardiopulmonary Resuscitation (CPR) Training Rates in the United States (2012) (0)
Quality of Life and Type of Cardiac Resynchronization Therapy Device in Older Heart Failure Patients. (2022) (0)
Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials (2023) (0)
Comparative Effectiveness of Left Atrial Appendage Occlusion Versus Oral Anticoagulation by Sex (2023) (0)
VIth International Symposium on Interventional Electrophysiology in the Management of Cardiac Arrhythmias (2011) (0)
Antiarrhythmic Drug Use in Patients <65 Years of Age With Atrial Fibrillation and Without Structural Heart Disease (2015) (0)
DEVELOPING A RISK MODEL FOR IN-HOSPITAL ADVERSE OUTCOMES FOLLOWING ICD IMPLANTATION: RESULTS FROM THE NCDR® (2013) (0)
Table B, Key findings and strength of evidence for Key Question 1: Short-term (≤12 months) comparative efficacy and effectiveness of RFA versus medical therapy for AF (2015) (0)
Figure 9, Forest plot for restoration of sinus rhythm for amiodarone versus sotalol (2013) (0)
Abstract 15523: Biomarkers Predict Cause of Death More Accurately Than Clinical Variables in Patients With Atrial Fibrillation on Oral Anticoagulation - Results From the ARISTOTLE Trial (2016) (0)
Table H5, Table of FDA-Approved Catheter Ablation Devices (2015) (0)
Abstract 17236: Intracranial Hemorrhage in Patients With Atrial Fibrillation in the ARISTOTLE Trial: Clinical Characteristics and Associated Outcomes (2015) (0)
Improved patient selection for implantable defibrillators (2019) (0)
RECONSIDERING APPROPRIATE DOFETILIDE DOSING IN WOMEN (2015) (0)
Abstract 14804: Complications and Mortality Following CRT-D versus ICD Implants in Older Medicare Beneficiaries (2020) (0)
Assessing the appropriateness of ICD use "appropriately". (2015) (0)
IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR (ICD) UTILIZATION AMONG OLDER PATIENTS WITH LOW EJECTION FRACTION FOLLOWING CORONARY REVASCULARIZATION FOR MYOCARDIAL INFARCTION (2020) (0)
Abstract 10420: Utilization of Cardiac Resynchronization Therapy in Patients Hospitalized With Heart Failure: Has it Changed and is it Associated With Patient Outcomes? (2015) (0)
Table 7, Heart rate results (24-hour Holter monitor) (2013) (0)
Abstract 13168: Sustained Ventricular Tachycardia and Ventricular Fibrillation are Infrequent Events but are Associated with Increased Arrhythmic and All-cause Death Following Non-ST-Segment Elevation Acute Coronary Syndromes (2010) (0)
Abstract 16496: Longitudinal Outcomes After Implantation of a Subcutaneous or Transvenous Implantable Cardioverter Defibrillator in Older Patients: A Report From the National Cardiovascular Data Registry (2020) (0)
Facilitating Shared Decision Making Among Black Patients at Risk for Sudden Cardiac Arrest (2023) (0)
Implantable Cardioverter–Defibrillator Registries—What Have We Learned? (2011) (0)
Strength of Evidence Tables (2015) (0)
Complications from prophylactic replacement of cardiac implantable electronic device generators in response to FDA recall: a systematic review and meta-analysis (2015) (0)
Outcomes With Apixaban by Type of Atrial Fibrillation: Results From the Aristotle Trial (2012) (0)
Efficacy and Safety of Apixaban in Patients With Atrial Fibrillation According to Sex : Results From the ARISTOTLE Trial (2013) (0)

This paper list is powered by the following services:

Sana M. Al‐khatib's Academic­Influence.com Rankings

Sana M. Al‐khatib's Degrees

Why Is Sana M. Al‐khatib Influential?

Sana M. Al‐khatib's Published Works

Published Works

Sana M. Al‐khatib's AcademicInfluence.com Rankings